[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[HTML][HTML] Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One+ zero equals two?
P Eloy, R Le Grand, D Malvy, J Guedj - EBioMedicine, 2021 - thelancet.com
The route to an effective antiviral treatment against SARS-CoV-2 has been marked by
dozens of negative clinical trials, with thousands of patients across the globe enrolled in …
dozens of negative clinical trials, with thousands of patients across the globe enrolled in …
[HTML][HTML] Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study
Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
[HTML][HTML] Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Y Suzuki, Y Shibata, H Minemura, T Nikaido… - Clinical and …, 2023 - Springer
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …
Molnupiravir: A new candidate for COVID‐19 treatment
F Pourkarim, S Pourtaghi‐Anvarian… - Pharmacology …, 2022 - Wiley Online Library
The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …
and has rapidly spread to many countries around the world. The effective pharmacotherapy …
[HTML][HTML] Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a …
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
[HTML][HTML] Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
R Flisiak, D Zarębska-Michaluk, M Rogalska… - Pharmacological …, 2022 - Springer
Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
[HTML][HTML] Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2 …
WHK Schilling, P Jittamala, JA Watson… - The Lancet Infectious …, 2024 - thelancet.com
Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …
19 antiviral treatments, but their antiviral activities in patients have not been compared …
[HTML][HTML] Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
Molnupiravir, an oral antiviral treatment for COVID-19
Background Easily distributed oral antivirals are urgently needed to treat coronavirus
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …
disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of …